CHAMPION-PHOENIX: A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention

Deepak Bhatt et al

LAPLACE-2 TRIAL

Jennifer G Robinson, et al.

PARAMOUNT: Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction

Scott Solomon et al.

RELAX TRIAL: Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

Jhon Teerlink, Gad Cotter,Beth Davison, et al

STREAM-Strategic Reperfusion With Tenecteplase and Antithrombotic Treatment Early After Myocardial Infarction

Franz Van de Werf et al.

: PARADIGM-HF. Angiotensin-neprilysin inhibition versus enalapril in heart failure.

McMurray JJ, et al

ODYSSEY Long Term Study

Robinson JG et al

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Pablo Avanzas

6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial

Albert Ferro

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

Pablo Avanzas

Effect of Loading Dose of Atorvastatin Prior to Planned PCI: The SECURE-PCI Randomized Clinical Trial

Alberto J. Lorenzatti

Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Pablo Avanzas

A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest

Pablo Avanzas

Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE Trial)

Pablo Avanzas

Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients (CAMELLIA–TIMI 61)

Amelia Carro

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (MARINER)

Pablo del Castillo Vazquez,  Antoni Martínez-Rubio

Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure

Pablo Avanzas

Intravenous Iron in Patients Undergoing Maintenance Hemodialysis: the PIVOTAL trial

Sang Hong Baek

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

Krzysztof J. Filipiak

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia: The REDUCE-IT trial

Andréa Araujo Brandao

Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Ricardo Lopez Santi

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

Pablo Avanzas

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF) Study

Koji Hasegawa

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Celso Amodeo

Polypill as a Strategy for Primary and Secondary Cardiovascular Prevention

Edgardo Escobar

Antithrombotic Alone for Chronic Coronary Heart Disease and Nonvalvular Atrial Fibrillation

Gheorghe-Andrei Dan

SGLT2 Inhibitors Reduce Blood Pressure and Left Ventricular Mass

Thomas Kahan

Long-Term Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54

Pablo Avanzas

Impact of Renin–Angiotensin System Inhibitors on Transcatheter Aortic Valve Replacement: Analysis from PARTNER 2

Pablo Avanzas

Targeted Anti-Cytokine Therapies for Treatment of Atherothrombosis

Pablo Avanzas

Rivaroxaban in Peripheral Artery Disease after Revascularization

Gheorghe-Andrei Dan

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Edgardo Escobar

Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation

Augusto Gallino

Angiotensin-Neprilysin Inhibition as the First-Line Therapy for HF over ACE inhibitors?

Koji Hasegawa